drugset / Trial / NCT02926430
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to assess the safety and tolerability of 2 single doses of either 5\*10\^10 viral particles (vp) or 1\*10\^11 vp of Ad26.RSV.preF, administered intramuscularly to elderly adults given approximately 12 months apart.
Timeline
- Start
- 2016-11-08
- Primary completion
- 2018-03-14
- Completion
- 2019-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad26.RSV.preF | Vaccine | 5e+10 vg | Intramuscular |
| Subject | Ad26.RSV.preF | Vaccine | 1e+11 vg | Intramuscular |
Indications
No indication recorded.